Nanocoll

Chronic Pain

Poitiers University HospitalN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

80 Active assets in the Chronic Pain cohort.

Asset / Sponsor	Phase	Rating
(±)-TRAMADOL EMS	Phase 4	BBB
LIDOCAINE National and Kapodistrian University of Athens	Phase 4	BBB
NEPENTHE Bursa City Hospital	Phase 4	BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Stanford University	Phase 4	BBB
FENTANYL Aga Khan University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Nanocoll is also rated in:

head and neck cancerDormant

BB

Indicative ·

65 / 100

Non Endometrioid CarcinomaDormant

B

Indicative ·

60 / 100

Endometrioid CarcinomaDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.